Description
IGF::OT::IGF CONTRACTOR SHALL DEVELOP PRACTICAL, RELATIVELY INEXPENSIVE AND WIDELY DEPLOYABLE TECHNOLOGY BASED ON NEAR-INFRARED (NIR) OPTICAL SPECTROSCOPY TO ENABLE DEFINITIVE DIAGNOSES OF EARLY STAGE DEMENTIAS AND QUANTITATIVE MONITORING OF DISEASE PROGRESS AND RESPONSE TO TREATMENT. IN THIS PROJECT, THE FOCUS IS ALZHEIMER DISEASE (AD) BECAUSE OF ITS PUBLIC HEALTH IMPACT AND WELL-CHARACTERIZED NEUROPATHOLOGICAL PRESENTATION; DEMENTIA WITH LEWY BODIES (DLB) IS INCLUDED TO TEST AND DEVELOP THE POWER OF VA METHODS TO DIFFERENTIATE DISORDERS WITH OVERLAPPING CLINICAL AND NEUROPATHOLOGICAL FEATURES. THE SPECIFIC OBJECTIVE IS TO DEMONSTRATE THE CLINICAL FEASIBILITY OF ASSESSING HUMAN NEUROPATHOLOGY IN VIVO, BY MEANS OF NON-INVASIVE, NEAR-INFRARED, OPTICAL SPECTROSCOPY OF THE HUMAN BRAIN. VA AIMS ARE: 1) TO IDENTIFY THE UNIQUE SPECTROSCOPIC SIGNATURES OF PLAQUES, TANGLES, LEWY BODIES, NUCLEI, ETC. IN DIFFUSE SCATTERING OR REFLECTANCE SPECTRA OF BRAIN TISSUE; 2) TO DEVELOP MODELS OF LIGHT PROPAGATION IN THE ADULT HUMAN HEAD TO ENABLE EXTRACTION OF THESE UNIQUE SIGNATURES FROM SPECTRA OF THE BRAIN ACQUIRED NON-INVASIVELY; 3) TO DEVELOP NIR SPECTROSCOPY INSTRUMENTATION FOR ACQUIRING SUCH SPECTRA IN CLINICAL SETTINGS AND 4) TO DEMONSTRATE THE CLINICAL FEASIBILITY OF NEUROPATHOLOGIC ASSESSMENT BY NON-INVASIVE NIR SPECTROSCOPY TO ENABLE EARLY DETECTION OF DISEASE OR INJURY, USING PATIENTS IN THE REGIONAL GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER (GRECC) AND THE BOSTON UNIVERSITY ALZHEIMER S DISEASE CENTER (BUADC) OTHER FUNCTIONS
Modification chain · 1 transaction
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2014-05-08+$8,000= $8,000
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2014-05-08 | +$8,000 | $8,000 | IGF::OT::IGF CONTRACTOR SHALL DEVELOP PRACTICAL, RELATIVELY INEXPENSIVE AND WIDELY DEPLOYABLE TECHNOLOGY BASED… |
Related awards · 8
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI M9CXA49JQNL8)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| VA24113J0710 | 241-NETWORK CONTRACT OFFICE 01 · AN43 · R&D- MEDICAL: HEALTH SERVICES (ADVANCED DEVELOPMENT) | $50,000 | FY2013 |
| VA24112J0957 | 241-NETWORK CONTRACT OFFICE 01 · AN92 · R&D- MEDICAL: OTHER (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT) | $150,000 | FY2012 |
| VA24112D0126 | 241-NETWORK CONTRACT OFFICE 01 · AN43 · R&D- MEDICAL: HEALTH SERVICES (ADVANCED DEVELOPMENT) | $0 | FY2012 |
Other recipients under AN43 from 241-NETWORK CONTRACT OFFICE 01 (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| VA24112J1363 | MARCUS, SUE M | 241-NETWORK CONTRACT OFFICE 01 | $9,000 | FY2012 |
| VA24112D0233 | MARCUS, SUE M | 241-NETWORK CONTRACT OFFICE 01 | $0 | FY2012 |
| VA405D15002 | TENER CONSULTING GROUP LLC | 241-NETWORK CONTRACT OFFICE 01 | $5,589 | FY2011 |
| VA241P1310 | SUPERVALU INC. | 241-NETWORK CONTRACT OFFICE 01 | $0 | FY2009 |
| V650D95014 | NEXT STEP BIONICS AND PROSTHETICS INC | 241-NETWORK CONTRACT OFFICE 01 | $23,707 | FY2009 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA24114J1155_3600_VA24112D0126_3600 · retrieved 2026-09-26.